According to Cosmetics Business, Galderma has agreed to acquire 100% of ZO Skin Health for US$1.5 billion in an all-cash transaction funded by existing cash reserves and bank financing.

The Switzerland-based company, whose portfolio spans injectable aesthetics, dermatological skincare and therapeutic dermatology, expects the deal to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary closing conditions.

ZO Skin Health, a US physician-dispensed brand, recorded net sales of approximately $330 million in the twelve months to June 2026 and is sold through more than 16,500 physicians, medical spas and online accounts across more than 40 countries.

ZO will sit alongside Galderma's flagship Cetaphil and Alastin brands.

The surprising element is the price and the positioning: Cosmetics Business notes ZO Skin Health was built by dermatologist Dr Zein Obagi in 2007 around clinical science and a protocol-based daily regimen centered on retinol- and acid-based products, and Galderma says that approach complements Alastin's peptide-based regenerative pre- and post-procedure offering.

Obagi called ZO Skin Health his life's work and said he was confident it had found a home where its philosophy will endure and grow.

Cosmetics Business also reports the transaction is expected to be slightly dilutive to Galderma's core EBITDA margin in 2027, reaching a margin broadly comparable with the group average from 2028 onwards — a cost Galderma is clearly willing to pay.

The move lands just as Glamour South Africa reports a warning about the opposite end of the market: viral TikTok skincare routines.

According to Glamour, research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 followed 94 dermatology patients for 12 months who developed new or aggravated skin conditions after using products promoted on social media.

Glamour reports the most common issue was irritant contact dermatitis in 42% of patients, nearly 30% developed acne or worsened acne, and about 35% had adverse reactions to chemical exfoliants containing AHA or BHA.

Dermatologists cited by Glamour say social media-inspired routines often stack too many irritating actives.

Cosmetics Business says Galderma plans to increase commercial investment in ZO during the first year of ownership to strengthen the foundation for renewed growth beginning in the second year after closing.

CEO Flemming Ørnskov told the outlet the acquisition builds the world's most innovative dermatology portfolio and positions Galderma to compete in the fast-growing medical-grade skincare segment.

The clinical framing contrasts sharply with the influencer-driven routines Glamour describes, where dermatologists advise running new products past a dermatologist and adding only one new product every one to two weeks.

For beauty readers, the throughline is a market splitting between medical-grade science and viral content.